Saturday 17 October 2026 Export ATRA’s income statement to Excel — free account

Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $120.8 million, down 6.33% from fiscal 2024. In the quarter to June 2026, revenue fell 96.4%, EPS fell 260.0% and free cash flow grew 52.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

9.18 0.47 −4.87%

Follow ATRA

Alert me

Market cap: $96.9M
P/E: 0.0×
Fwd P/E: −8.4×
Dividend yield: —
F-score: 5/9
Altman Z: −125.91
Beneish M: 16.88
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 5.74

Total sells 3.85

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	1	—	—	—	1	—
Sell	2	—	1	—	2	—	3	—	—	1	—	—

Insider Ownership 53.90%

Capital & Financial Ratios $m

Market Cap 96.86

Revenue 6.19

Net Income (16.69)

Free Cash Flow (21.89)

Net Debt (9.87)

Current Ratio 1.98

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (8.37)

P/S ratio 22.28

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth (126.90%)

Next Y EPS Growth 236.15%

Next Y revenue growth (97.64%)

Next 5Y EPS Growth 58.27%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 80.55%

10-year low 10-year high

EV/Sales against its own 10 years 89.90%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	52	43	8	10
Receivables	34	1	1	0
Inventory	10	11	—	—
Other	6	10	2	3
	102	65	12	14

	2023	2024	2025	Q'26
Payables	4	4	0	1
ST’ Debt	—	—	—	—
Other	32	21	13	4
	142	135	15	7

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	23.85%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	1	—	—	—
’25	98	18	3	2	121
’24	27	29	40	33	129
’23	1	1	2	4	9
’22	7	52	4	0	64

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(3)	—	—	—
’25	(28)	(7)	(10)	(6)	(51)
’24	(30)	(11)	(4)	(24)	(69)
’23	(38)	(53)	(51)	(50)	(193)
’22	(85)	(64)	(65)	(57)	(270)
’21	(66)	(62)	(59)	(34)	(221)
’20	(67)	(57)	(53)	(4)	(181)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(3)	—	—	—
’25	(28)	(7)	(10)	(5)	(50)
’24	(30)	(11)	(4)	(25)	(69)
’23	(39)	(53)	(52)	(50)	(194)
’22	(87)	(65)	(65)	(57)	(275)
’21	(68)	(64)	(63)	(37)	(231)
’20	(68)	(59)	(53)	(5)	(185)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.29)	(0.32)	—	—	—
’25	3.50	0.19	(0.32)	(0.25)	2.57
’24	(5.75)	(3.10)	(2.93)	(1.19)	(11.41)
’23	(18.00)	(17.00)	(16.50)	(14.00)	(65.25)
’22	(21.75)	4.50	(20.50)	(18.00)	(56.00)
’21	(21.50)	(22.75)	(22.50)	(24.00)	(90.75)
’20	(30.00)	(28.50)	(23.00)	(23.75)	(103.75)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	311.25	295.00	415.00	259.50	113.00	295.25	70.75	4.98	6.50	5.01	Analyst estimates 2026–2028 Powerpack
	High	650.00	575.00	1,361.25	1,049.25	705.00	546.25	423.25	141.00	39.50	18.95
People
People	Employees	96	185	311	393	437	578	334	225	153	14
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.04	0.19	0.04	0.84	8.63
Income, $m
Income, $m	Revenue	—	—	—	—	—	20	64	9	129	121
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	100.00	100.00	(3.65)	83.71	82.44
	EBT	(79)	(120)	(231)	(291)	(307)	(340)	(228)	(276)	(85)	33
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	(1,672.05)	(359.10)	(3,220.70)	(66.24)	27.09
	Net income	(79)	(119)	(231)	(291)	(307)	(340)	(228)	(276)	(85)	33
	Depreciation	3	2	2	6	9	11	7	6	5	2
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	5.43	15.58	2.02	17.22	9.63
	Earnings	(68.75)	(100.00)	(131.75)	(141.75)	(103.75)	(90.75)	(56.00)	(65.25)	(11.41)	2.61
	Cash flow	(52.23)	(73.25)	(102.59)	(114.81)	(61.09)	(58.86)	(66.29)	(45.56)	(9.18)	(4.06)
	Capex	(2.63)	(16.94)	(20.50)	(2.71)	(1.53)	(2.82)	(1.03)	(0.28)	(0.03)	0.08
	Free cash flow	(54.86)	(90.19)	(123.09)	(117.53)	(62.62)	(61.68)	(67.32)	(45.84)	(9.21)	(3.99)
	Book value	220.77	148.90	193.37	141.69	156.25	74.63	31.04	(23.43)	(12.99)	(3.07)
	Shares, m	1	1	2	2	3	4	4	4	7	13
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	0.00	0.00	0.00	0.00	5.72
	P/S	—	—	—	—	—	72.58	5.26	5.93	0.77	1.88
	P/B	—	—	—	—	—	5.28	2.64	0.00	0.00	0.00
	EV/Sales	—	—	—	—	—	54.33	1.44	(0.12)	0.44	1.81
	EV/FCF	—	—	—	—	—	(4.78)	(0.33)	0.01	(0.83)	(4.36)
Cash, $m
Cash, $m	Operating cash flow	(60)	(88)	(180)	(236)	(181)	(221)	(270)	(193)	(69)	(51)
	Capex	(3)	(20)	(36)	(6)	(5)	(11)	(4)	(1)	0	1
	Free cash flow	(63)	(108)	(216)	(241)	(185)	(231)	(275)	(194)	(69)	(50)
Balance, $m
Balance, $m	Working capital	251	145	282	236	440	279	216	(40)	(70)	(3)
	Total debt	—	1	1	16	15	28	72	—	—	—
	Net debt	(256)	(166)	(310)	(259)	(501)	(371)	(243)	(52)	(43)	(8)
	Shareholders’ equity	254	178	339	291	462	280	127	—	(97)	(39)
Returns, %
Returns, %	ROA	(26.85)	(49.61)	(75.69)	(79.20)	(65.86)	(64.41)	(54.06)	(101.91)	(62.20)	50.55
	ROIC	0.00	(656.28)	(510.45)	(587.08)	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(27.79)	(55.37)	(89.29)	(92.43)	(81.43)	(91.69)	(112.39)	(2,014.86)	86.92	(48.15)

Negative figures in brackets.

value withheld pending a data check

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MIST Milestone Pharmaceuticals Inc.	$98.9M	— (loss-making)	— (loss-making)	−62.73% (below 0%: shrinking)	n/m	−80.81% (below 0%: shrinking)	94.28%	(4,584.97%)	Compare
CBUS Cibus, Inc.	$98.6M	— (loss-making)	— (loss-making)	+6.54% (above 0%: growing)	n/m	+31.62% (above 0%: growing)	100.00%	(1,300.30%)	Compare
PMVP PMV Pharmaceuticals, Inc.	$97.4M	— (loss-making)	—	—	n/m	+20.27% (above 0%: growing)	0.00%	0.00%	Compare
NRXS Neuraxis, Inc.	$97.2M	— (loss-making)	— (loss-making)	+115.71% (above 0%: growing)	n/m	+29.76% (above 0%: growing)	85.87%	(110.16%)	Compare
IMUX Immunic, Inc.	$96.9M	— (loss-making)	—	—	n/m	−26.79% (below 0%: shrinking)	0.00%	0.00%	Compare
ATRA Atara Biotherapeutics, Inc.	$96.9M	— (loss-making)	— (loss-making)	−96.42% (below 0%: shrinking)	n/m	+52.10% (above 0%: growing)	69.68%	(749.21%)
ANIX ANIXA BIOSCIENCES INC	$96.7M	— (loss-making)	— (loss-making)	0.00%	n/m	−17.14% (below 0%: shrinking)	0.00%	0.00%	Compare
ICCC ImmuCell Corporation	$95.9M	126×	— (loss-making)	+11.50% (above 0%: growing)	+233.33% (above 0%: growing)	+54.86% (above 0%: growing)	33.92%	26.93%	Compare
RANI Rani Therapeutics Holdings, Inc.	$94.8M	— (loss-making)	— (loss-making)	0.00%	n/m	−55.29% (below 0%: shrinking)	100.00%	(516.86%)	Compare
Median of peers	$97.0M	—	—	+3.27%	—	+1.56%	59.90%	(55.08%)

All 614 Biotechnology stocks →

Atara Biotherapeutics, Inc. (ATRA) key facts

Concern: Atara Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $120.8 million, down 6.33% from fiscal 2024.
Atara Biotherapeutics, Inc. (ATRA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ATRA traded at $9.18, a market capitalization of $96.9 million.
Return on equity was −48.2% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −125.91 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.